Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.65 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 6/20 | 0.47 |
| ▸ | ITK | Q08881 | 6/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.45 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18987161 | 0.84 | IDO1 (0.53) | USP30IDO1TDO2L3MBTL1 | |
| SCHEMBL19017747 | 0.84 | USP30 (0.77) | USP30LCKITKPCSK9OTUD7B | |
| SCHEMBL19017745 | 0.81 | USP30 (0.64) | USP30IDO1TDO2GPR119ROCK2 | |
| SCHEMBL28600309 | 0.81 | USP30 (0.64) | USP30IDO1TDO2GPR119ROCK2 | |
| SCHEMBL29908199 | 0.81 | USP30 (0.64) | USP30IDO1TDO2GPR119ROCK2 | |
| SCHEMBL3748609 | 0.81 | KMT2A (0.48) | USP30IDO1TDO2L3MBTL1 | |
| SCHEMBL24977487 | 0.81 | USP30 (0.72) | USP30LCKITKPCSK9OTUD7B | |
| SCHEMBL18987081 | 0.79 | USP30 (1.00) | USP30PCSK9OTUD7B | |
| SCHEMBL31286843 | 0.79 | L3MBTL1 (0.48) | USP30IDO1TDO2PIK3CAPI4KA | |
| SCHEMBL30248411 | 0.77 | ABL1 (0.56) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-3390391-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2022-09-14 | — | — | EP | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-11130748-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| US-11130748-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| CN-108368089-B | Deubiquitinase inhibitor | 特殊治疗有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-20200172516-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172516-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| EP-3390391-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103614-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017103614-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380562-A1 | Novel Compounds | USP30, USP20, USP10 | USP30 1/4885IDO1 2211/4885TDO2 4035/4885 |
| US-11130748-B2 | Compounds | USP30, USP20, USP10 | USP30 1/4885IDO1 2065/4885TDO2 3985/4885 |
| US-20200172516-A1 | Novel Compounds | USP30, USP20, USP10 | USP30 1/4885IDO1 2211/4885TDO2 4035/4885 |
| US-11958833-B2 | Compounds | USP30, USP20, USP10 | USP30 1/4885IDO1 2065/4885TDO2 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.